Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVX ABIVAX Société Anonyme	$6.01 +0.3%	$6.40	$4.77 ▼ $14.72	$381.15M	0.29	133,790 shs	120,156 shs
PGEN Precigen	$1.45 +10.7%	$1.50	$0.65 ▼ $2.17	$386.67M	1.82	1.31 million shs	2.87 million shs
SGMT Sagimet Biosciences	$3.22 -2.7%	$3.06	$1.73 ▼ $7.38	$98.77M	2.32	862,032 shs	350,568 shs
TRML Tourmaline Bio	$16.56 +6.7%	$15.62	$11.56 ▼ $29.79	$425.34M	2.11	269,912 shs	211,009 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVX ABIVAX Société Anonyme	0.00%	-10.43%	-6.09%	-18.78%	-56.92%
PGEN Precigen	0.00%	+9.02%	+4.32%	-26.02%	+0.69%
SGMT Sagimet Biosciences	0.00%	-0.62%	+45.70%	-24.24%	-30.30%
TRML Tourmaline Bio	0.00%	+9.74%	+3.44%	+19.74%	+8.59%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABVX ABIVAX Société Anonyme	2.6495 of 5 stars	3.5	4.0	0.0	2.6	0.8	0.6
PGEN Precigen	3.6312 of 5 stars	3.5	0.0	4.7	2.2	1.7	0.6
SGMT Sagimet Biosciences	2.3001 of 5 stars	3.4	2.0	0.0	2.0	2.5	0.6
TRML Tourmaline Bio	2.2851 of 5 stars	3.5	3.0	0.0	1.9	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABVX ABIVAX Société Anonyme	3.00	Buy	$34.00	465.72% Upside
PGEN Precigen	3.00	Buy	$7.00	382.76% Upside
SGMT Sagimet Biosciences	2.80	Moderate Buy	$22.40	595.65% Upside
TRML Tourmaline Bio	3.00	Buy	$49.33	197.91% Upside

Current Analyst Ratings Breakdown

Latest SGMT, ABVX, TRML, and PGEN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/15/2025	PGEN Precigen	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
5/5/2025	TRML Tourmaline Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$70.00 ➝ $70.00
5/5/2025	TRML Tourmaline Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $50.00
4/30/2025	ABVX ABIVAX Société Anonyme	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$33.00 ➝ $33.00
4/23/2025	TRML Tourmaline Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$70.00
3/20/2025	ABVX ABIVAX Société Anonyme	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Equal Weight	$12.00
3/20/2025	PGEN Precigen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00
3/14/2025	TRML Tourmaline Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$42.00 ➝ $43.00
3/14/2025	TRML Tourmaline Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$49.00 ➝ $50.00
3/11/2025	SGMT Sagimet Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00
3/6/2025	TRML Tourmaline Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$42.00

(Data available from 5/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABVX ABIVAX Société Anonyme	N/A	N/A	N/A	N/A	$3.37 per share	N/A
PGEN Precigen	$3.93M	109.04	N/A	N/A	$0.48 per share	3.02
SGMT Sagimet Biosciences	$2M	49.39	N/A	N/A	$3.98 per share	0.81
TRML Tourmaline Bio	N/A	N/A	N/A	N/A	$10.08 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABVX ABIVAX Société Anonyme	-$159.90M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
PGEN Precigen	-$95.90M	-$0.56	N/A	N/A	N/A	-3,521.68%	-123.06%	-87.33%	N/A
SGMT Sagimet Biosciences	-$27.88M	-$1.76	N/A	N/A	N/A	N/A	-23.63%	-22.91%	5/21/2025 (Estimated)
TRML Tourmaline Bio	-$42.12M	-$3.21	N/A	N/A	N/A	N/A	-20.97%	-20.56%	N/A

Latest SGMT, ABVX, TRML, and PGEN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/21/2025	Q1 2025	SGMT Sagimet Biosciences	-$0.79	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	PGEN Precigen	-$0.08	-$0.07	+$0.01	-$0.18	$0.50 million	$1.34 million
5/8/2025	Q1 2025	SGMT Sagimet Biosciences	-$0.79	-$0.56	+$0.23	-$0.56	N/A	N/A
5/2/2025	Q1 2025	TRML Tourmaline Bio	-$0.91	-$0.89	+$0.02	-$0.89	N/A	N/A
3/19/2025	Q4 2024	PGEN Precigen	-$0.06	-$0.04	+$0.02	-$0.06	$1.30 million	$1.19 million
3/13/2025	Q4 2024	TRML Tourmaline Bio	-$0.91	-$0.86	+$0.05	-$0.86	N/A	$0.04 million
3/12/2025	Q4 2024	SGMT Sagimet Biosciences	-$0.65	-$0.50	+$0.15	-$0.50	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABVX ABIVAX Société Anonyme	N/A	N/A	N/A	N/A	N/A
PGEN Precigen	N/A	N/A	N/A	N/A	N/A
SGMT Sagimet Biosciences	N/A	N/A	N/A	N/A	N/A
TRML Tourmaline Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABVX ABIVAX Société Anonyme	0.48	3.04	N/A
PGEN Precigen	N/A	1.63	1.63
SGMT Sagimet Biosciences	N/A	38.41	38.41
TRML Tourmaline Bio	N/A	40.33	40.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABVX ABIVAX Société Anonyme	47.91%
PGEN Precigen	33.51%
SGMT Sagimet Biosciences	87.86%
TRML Tourmaline Bio	91.89%

Insider Ownership

Company	Insider Ownership
ABVX ABIVAX Société Anonyme	N/A
PGEN Precigen	44.90%
SGMT Sagimet Biosciences	14.70%
TRML Tourmaline Bio	11.02%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABVX ABIVAX Société Anonyme	61	63.42 million	N/A	Not Optionable
PGEN Precigen	190	295.17 million	161.37 million	Optionable
SGMT Sagimet Biosciences	8	30.68 million	25.28 million	Optionable
TRML Tourmaline Bio	44	25.69 million	22.82 million	Optionable

SGMT, ABVX, TRML, and PGEN Headlines

Recent News About These Companies

Contrasting Exelixis (NASDAQ:EXEL) & Tourmaline Bio (NASDAQ:TRML)

May 16 at 2:25 AM | americanbankingnews.com

Analysts Set Expectations for Tourmaline Bio FY2025 Earnings

May 10, 2025 | marketbeat.com

Leerink Partnrs Comments on Tourmaline Bio FY2025 Earnings

May 10, 2025 | marketbeat.com

Tourmaline Bio (TRML) Expected to Announce Quarterly Earnings on Monday

May 10, 2025 | americanbankingnews.com

Brokers Set Expectations for Tourmaline Bio FY2025 Earnings

May 9, 2025 | marketbeat.com

Q2 EPS Estimates for Tourmaline Bio Decreased by Analyst

May 9, 2025 | marketbeat.com

Leerink Partnrs Weighs in on Tourmaline Bio Q2 Earnings

May 9, 2025 | marketbeat.com

Alyeska Investment Group L.P. Lowers Position in Tourmaline Bio, Inc. (NASDAQ:TRML)

May 9, 2025 | marketbeat.com

HC Wainwright Lowers Earnings Estimates for Tourmaline Bio

May 9, 2025 | americanbankingnews.com

HC Wainwright Weighs in on Tourmaline Bio Q2 Earnings

May 8, 2025 | marketbeat.com

FY2025 EPS Estimates for Tourmaline Bio Increased by Analyst

May 8, 2025 | americanbankingnews.com

Brokers Offer Predictions for Tourmaline Bio Q2 Earnings

May 8, 2025 | americanbankingnews.com

Analysts Set Tourmaline Bio, Inc. (NASDAQ:TRML) Price Target at $49.33

May 8, 2025 | americanbankingnews.com

Tourmaline Bio (NASDAQ:TRML) Receives "Buy" Rating from HC Wainwright

May 7, 2025 | marketbeat.com

Tourmaline Bio's (TRML) "Buy" Rating Reiterated at Chardan Capital

May 7, 2025 | marketbeat.com

Tourmaline Bio (TRML) Expected to Announce Earnings on Monday

May 7, 2025 | marketbeat.com

Tourmaline Bio, Inc. (NASDAQ:TRML) Shares Purchased by Barclays PLC

May 7, 2025 | marketbeat.com

Tourmaline Bio Reports Q1 2025 Financial Results

May 7, 2025 | tipranks.com

Susquehanna Fundamental Investments LLC Invests $467,000 in Tourmaline Bio, Inc. (NASDAQ:TRML)

May 6, 2025 | marketbeat.com

Tourmaline Bio, Inc. (NASDAQ:TRML) Receives Average Rating of "Buy" from Brokerages

May 6, 2025 | marketbeat.com

Tourmaline Bio (NASDAQ:TRML) Issues Earnings Results

May 4, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGMT, ABVX, TRML, and PGEN Company Descriptions

ABIVAX Société Anonyme NASDAQ:ABVX

$6.02 +0.04 (+0.58%)

As of 05/16/2025 04:00 PM Eastern

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

Precigen NASDAQ:PGEN

$1.45 +0.14 (+10.69%)

Closing price 05/16/2025 04:00 PM Eastern

Extended Trading

$1.46 +0.01 (+0.97%)

As of 05/16/2025 07:56 PM Eastern

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Sagimet Biosciences NASDAQ:SGMT

$3.22 -0.09 (-2.72%)

Closing price 05/16/2025 04:00 PM Eastern

Extended Trading

$3.20 -0.02 (-0.47%)

As of 05/16/2025 07:27 PM Eastern

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

Tourmaline Bio NASDAQ:TRML

$16.56 +1.04 (+6.70%)

Closing price 05/16/2025 04:00 PM Eastern

Extended Trading

$16.56 0.00 (-0.03%)

As of 05/16/2025 07:23 PM Eastern

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time